Literature DB >> 14518709

Humoral immune response against hepatitis C virus.

R Burioni1, N Mancini, F Canducci, S Carletti, A Grieco, M Perotti, G Serafini, E Berardinelli, S Bighi, P E Varaldo, M Clementi.   

Abstract

Antibodies are in several instances a reliable marker indicating vigorous immune response against infectious agents and in several viral diseases presence in the blood of specific anti-viral antibodies indicates an effective protection. However, this is not always true. For example, in the case of hepatitis C virus (HCV) an important human pathogen considered the causative agent of the nonA- nonB hepatitis, in spite of an intense antibody response there is no protection against a new infection and in the majority of infected individuals the virus overcomes host defences establishing a persistent infection. Here we describe how the dissection of the humoral immune response against HCV glycoprotein E2 of infected patients was useful for a better comprehension of the virus-host interplay. Cross-reactive antibodies directed against E2 are produced by the HCV-infected patient, but not all of them are protective, and some could even result to be detrimental for the patient. The cross-reactive anti-HCV/E2 humoral antibody response is complex and not necessarily completely beneficial to the host.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14518709

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  6 in total

1.  Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein.

Authors:  Mario Perotti; Nicasio Mancini; Roberta A Diotti; Alexander W Tarr; Jonathan K Ball; Ania Owsianka; R Adair; Arvind H Patel; Massimo Clementi; Roberto Burioni
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

2.  Characterization of Anti-HCV Antibodies in IL-10-Treated Patients.

Authors:  Erika A Eksioglu; Jennifer Bess; Graham Jones; Jennifer Dettloff; Parinda Dangmeon; Hui-Jia Dong; Haizhen Zhu; Roberto Firpi; Yiling Xu; David R Nelson; Chen Liu
Journal:  Viral Immunol       Date:  2010-08       Impact factor: 2.257

3.  Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization.

Authors:  Emilia Falkowska; Francis Kajumo; Edie Garcia; John Reinus; Tatjana Dragic
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

4.  Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein.

Authors:  Giuseppe A Sautto; Karin Wisskirchen; Nicola Clementi; Matteo Castelli; Roberta A Diotti; Julia Graf; Massimo Clementi; Roberto Burioni; Ulrike Protzer; Nicasio Mancini
Journal:  Gut       Date:  2015-02-06       Impact factor: 23.059

Review 5.  Multiantibody strategies for HIV.

Authors:  Andrew Hiatt; Larry Zeitlin; Kevin J Whaley
Journal:  Clin Dev Immunol       Date:  2013-06-06

Review 6.  Neutralization interfering antibodies: a "novel" example of humoral immune dysfunction facilitating viral escape?

Authors:  Mancini Nicasio; Giuseppe Sautto; Nicola Clementi; Roberta A Diotti; Elena Criscuolo; Matteo Castelli; Laura Solforosi; Massimo Clementi; Roberto Burioni
Journal:  Viruses       Date:  2012-09-24       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.